

1 **Supporting Information**

2 **Analysis of Cannabinoids and Their Metabolites in Human Urine**

3 Binnian Wei¹, Lanqing Wang¹, Benjamin C. Blount¹

4 ¹ Division of Laboratory Sciences, National Center for Environmental Health, Centers for
5 Disease Control and Prevention, Atlanta, Georgia, USA

6 * Corresponding author: Telephone: +1 770-488-4564. E-mail: bwei@cdc.gov.

7
8 **Table of Contents**

9 **Experimental Section** 2

10 Chemicals and Materials 2

11 Standard Solution Preparation 2

12 Ultra-High Pressure Liquid Chromatograph (UHPLC) 3

13 Determination of Extraction Recoveries and Matrix Effects. 3

14 Analytical Specificity 3

15 Data analysis and software 4

16 Table S–1: UHPLC gradient Elution program..... 5

17 Table S–2: Multiple reaction monitoring (MRM) transitions and mass spectrometry settings. 6

18 Table S–3: Limit of detection (LOD) in terms of mass-on-column..... 7

19 Table S–4: Accuracy and precision of replicate analysis of five compounds in fortified urine
20 samples by “total” method (with enzymatic-alkaline hydrolysis)..... 8

21 Figure S–1: Cannabinoid and THC metabolites measured in this method 9

22 Additional information–S1: Complete method file for data acquisition..... 10

23 References 11

26 **Experimental Section**

27 **Chemicals and Materials**

28 We bought native and isotopically labeled standards, including THC, THC-*d*3,
29 COOH-THC, COOH-THC-*d*3, OH-THC, OH-THC-*d*3, CBD, CBD-*d*3, CBN and CBN-*d*3
30 from Cerilliant (Round Rock, TX, USA). We bought HPLC-grade methanol ($\geq 99.9\%$),
31 water, acetonitrile ($\geq 99.9\%$), 2-propanol ($\geq 99.9\%$), formic acid ($\geq 99.5\%$), and sodium
32 hydroxide solution (10N/certified) from Fisher Scientific (Fair Lawn, NJ, USA), ammonium
33 formate ($\geq 99\%$) and ammonium acetate ($\geq 98\%$) and β -glucuronidase/sulfatase
34 (*Escherichia coli*, type IX-A) from Sigma-Aldrich Laboratories, Inc. (St. Louis, MO, USA).
35 Solid phase extraction (SPE, C18, 100mg) 96-well plate was bought from Biotage
36 (Charlotte, NC, USA).

37 **Standard Solution Preparation**

38 We prepared 19 working solutions from serial dilutions of primary stock solutions
39 with methanol and water (v/v: 60:40), and stored them in Teflon-capped amber glass
40 vials at $-24\text{ }^{\circ}\text{C}$. We added 50 μL of each working solution to 500 μL of blank urine using
41 a Hamilton automated liquid-handling system (Reno, NV, USA) during sample
42 preparation. This automatically created calibrators at 0.001, 0.002, 0.005, 0.010, 0.020,
43 0.0625, 0.125, 0.250, 0.650, 1.25, 2.50, 5.0, 10, 25, 50, 100, 250, 500 and 800 ng/mL.
44 Primary standard solutions from different lot numbers were used to prepare QC samples.
45 We prepared three working solutions by diluting appropriate volumes of the primary
46 solutions with methanol and water (v/v: 60:40).

47 **Ultra-High Pressure Liquid Chromatograph (UHPLC)**

48 The UHPLC system consisted of a DGU-20A degasser, two LC-30AS pumps, a
49 SIL-30AC autosampler, and a CTO-20AC column oven (Shimadzu Corp, Columbia,
50 MD, USA).

51 **Determination of Extraction Recoveries and Matrix Effects.**

52 We used three sets of samples at low, medium and high concentrations (0.025, 25 and
53 500 ng/mL, respectively) to determine the optimized extraction recoveries and matrix
54 effects.(Wei *et al.*, 2014) In the first set, 12 blank urine samples were fortified with native
55 and deuterated internal standard solutions at the beginning of the sample preparation.
56 In the second set of 12 blank urine samples, spiking solutions were added immediately
57 before LC injection. The third set of 12 samples were prepared by spiking native and
58 internal standard solutions in methanol and water (v/v: 50:50). Sample extraction
59 recovery was estimated by dividing the average peak areas of set 1 by those of set 2
60 and then multiple by 100. The matrix effect was estimated by dividing the average peak
61 areas of set 2 by those of set 3 and subtracted from 1 and then multiple by 100.

62 **Analytical Specificity**

63 The analytical specificity in this method was assessed by following measures: (1) The
64 use of MS/MS allowed a means of monitoring ion transitions specific to each analyte;
65 (2) target native analyte should co-elute with the corresponding isotope labeled internal
66 standard analog (ISTD); (2) Bothe native analyte and ISTD should elute at the specific
67 retention time; (3) native analyte should have specific ratios of the quantitation

68 transition's response to the confirmation transition's response to confirm the analyte
69 determined in unknown samples. The quantitation and confirmation ion transitions for
70 each analyte are presented in Table S-2.

71 **Data analysis and software**

72 Analyst software (version 1.6.2) was used for data acquisition and quantitation.
73 Calibration curves were constructed using peak area ratios of analytes to corresponding
74 internal standards for each batch via linear least-squares regression with a $1/x$ weighting
75 factor.

76 Table S-1: UHPLC gradient Elution program.

Time	Module	Event	Parameter
0.01	System Controller	start	-
1.20	Pumps	%B	50
2.20	Pumps	%B	75
2.80	Pumps	%B	75
3.50	Pumps	%B	96
4.20	Pumps	%B	96
4.21	Pumps	%B	50
6.00	System Controller	Stop	

77

78 Table S–2: Multiple reaction monitoring (MRM) transitions and mass spectrometry settings.

Analyte	ESI mode	Precursor/ product ion (quant, confirm) ¹	Settings used in this study (volts) ²					Optimized CE
			DP	CE ³	CXP	EP	CE	
OHTHC	+	331.0/(193.1, 201)	40	34/33	11	10		
	–	329.1/(268.1, 311.2)	-55	-50/-35	-16	-10	-37/-26	
OHTHC-D3	+	334.1/196.1	50	35	11	8		
	–	332.1/314.2	-50	-26	-16	-10		
COOH-THC	+	345.1/(193.1, 299.2)	50	37/28	16	10		
	–	343.2/(191, 245)	-65	-54/-46	-15	-10	-45/-37	
COOH-THC-D3	+	348.1/196.1	60	37	13	8		
	–	346.1/248.1	-60	-39	-16	-8		
CBD	+	315.2/(193.1, 123.1)	65	32/41	11	10		
	–	313.1/(245.1, 179)	-60	-47/-26	-16	-10	-33/-26	
CBD-D3	+	318.2/196.2	50	31	13	8		
	–	316.1/248.1	-60	-33	-16	-10		
CBN	+	311.1/(208, 241)	55	40/26	11	10		
	–	309.1/(279.1, 222.1)	-60	-62/-60	-16	-10	-44/-58	
CBN-D3	+	314.2/223.1	55	30	13	7		
	–	312.1/282	-60	-44	-16	-10		
THC	+	315.1/(193.1, 123.1)	65	32/41	11	10		
	–	313.2/(245.2, 191)	-60	-50/-39	-16	-10	-36/-39	
THC-D3	+	318.1/196.1	60	32	12	8		
	–	316.1/248.2	-60	-37	-16	-10		

79 Abbreviations: ESI – electrospray ionization; DP – declustering potential; CE – collision offset energy; CXP – collision cell
80 exit potential; EP – entrance potential.¹ two ion transitions for each native analyte (quantitation/confirmation) and one
81 transition for labeled standard were monitored. ² CE values under negative ESI were detuned from the optimized values
82 to higher levels to yield lower analytical responses. ³ Collision energy: quantitation/confirmation transitions

83 Table S–3: Limit of detection (LOD) in terms of mass-on-column.

Analyte	LOD, ng/mL	LOD, pmol/mL	LOD, pg on-column ²	LOD, fmol on-column ³
	“free”/“total” ₁	“free”/“total”	“free”/“total”	“free”/“total”
OHTHC	0.008/0.017	0.024/0.051	0.08/0.17	0.242/0.514
COOH-THC	0.005/0.015	0.015/0.044	0.05/0.15	0.145/0.435
CBD	0.004/0.009	0.013/0.029	0.04/0.09	0.127/0.286
CBN	0.002/0.007	0.006/0.023	0.02/0.07	0.064/0.225
THC	0.002/0.005	0.006/0.016	0.02/0.05	0.064/0.159

84 Abbreviations: pmol – picomole. pg – picogram. fmol – femtomole.

85 ¹ “Free” and “total” refer to unconjugated and the sum of conjugated and unconjugated forms,
 86 respectively.

87 ² LOD in terms of pg on-column was calculated as: LOD (ng/mL)×0.01mL (injection volume)
 88 ×10³×pg/ng

89 ³ LOD in terms of fmol-on-column was calculated as: LOD (ng/mL)×0.01mL (injection volume)
 90 ×(1/Molecular weight)×nmol/ng×10⁶×fmol/nmol


91 Table S-4: Accuracy and precision of replicate analysis of five compounds in fortified
 92 urine samples by “total” method (with enzymatic-alkaline hydrolysis).

	ESI mode	Target, ng/mL	Within-Day			Between-day		
			measured	Error %	RSD %	measured	Error %	RSD %
OHTHC	+	0.050	0.0484	-3.2	8.1	0.0522	4.3	3.2
		0.100	0.103	3.0	8.0	0.103	2.8	6.1
		1.25	1.32	5.3	5.3	1.28	2.6	3.2
		25.0	27.0	7.8	4.4	27.4	9.7	3.5
	-	25.0	26.8	7.1	6.3	27.0	7.9	4.1
		100	108	7.7	1.5	105	4.5	2.1
		500	501	0.2	3.4	487	-2.6	4.7
COOH-THC	+	0.050	0.0494	-1.2	6.9	0.0504	0.8	7.7
		0.100	0.104	4.3	6.7	0.105	5.0	4.8
		1.25	1.25	0.3	7.4	1.25	-0.4	3.8
		25.0	27.2	8.8	3.0	26.6	6.6	2.6
	-	25.0	26.5	6.0	5.5	26.7	6.7	4.4
		100	106	5.7	5.7	109	8.5	4.0
		500	472	-5.6	6.1	462	-7.7	2.6
CBD	+	0.050	0.0519	3.8	9.3	0.0518	3.6	8.2
		0.100	0.096	-4.1	7.9	0.106	6.3	5.5
		1.25	1.15	-8.0	4.5	1.27	1.2	3.6
		25.0	25.2	0.8	4.7	25.2	1.0	4.4
	-	25.0	25.2	0.8	6.6	25.3	1.1	7.2
		100	105	5.0	2.0	108	7.5	3.3
		500	461	-7.8	2.6	459	-8.2	3.1
CBN	+	0.050	0.0512	2.5	7.5	0.0524	4.7	6.1
		0.100	0.094	-6.1	6.8	0.105	5.1	8.3
		1.25	1.23	-1.3	4.0	1.26	0.4	3.8
		25.0	26.0	4.0	4.5	26.6	6.2	4.1
	-	25.0	25.9	3.6	5.8	25.7	2.7	4.5
		100	100	0.3	1.6	99.9	-0.1	3.7
		500	476	-4.8	2.6	484	-3.3	3.3
THC	+	0.050	0.0465	-7.1	7.1	0.0538	7.6	8.4
		0.100	0.094	-5.6	4.8	0.105	5.1	6.2
		1.25	1.21	-3.5	5.1	1.25	-0.2	2.3
		25.0	27.0	8.2	3.4	27.0	8.1	2.9
	-	25.0	26.9	7.6	4.5	27.2	8.9	5.7
		100	104	4.3	0.6	106	6.3	2.2
		500	480	-3.9	4.0	483	-3.4	2.8

93 Abbreviation: ESI = electrospray ionization; RSD = relative standard deviation

94 Figure S-1: Cannabinoid and THC metabolites measured in this method

95



96

97

98 Additional information—S1: Complete method file for data acquisition
99 The instrument method file used for data acquisition in this study can be obtained upon
100 request.

101

102 **References**

103 Wei, B., J. Feng, I.J. Rehmani, S. Miller, J.E. McGuffey, B.C. Blount and L. Wang, 2014. A high-throughput
104 robotic sample preparation system and hplc-ms/ms for measuring urinary anatabine, anabasine,
105 nicotine and major nicotine metabolites. *Clin Chim Acta*, 436: 290-297.

106